杆菌对肝细胞癌免疫检查点抑制的影响:一个多中心研究
Najib Ben Khaled1,2,3, Christian Schulz4,5, Marianna Alunni-Fabbroni6
1Department of Medicine II, University Hospital, LMU Munich, Munich, Germany, najib.benkhaled@med.uni-muenchen.de.
Digestion
|February 19, 2025
概括
杆菌 (H. pylori) 感染与接受免疫检查点抑制剂 (ICI) 治疗的肝细胞癌 (HCC) 患者的情况恶化有关. 在接受基于索拉芬尼布的治疗方案的患者中没有观察到这种关联.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 杆菌 (H. pylori) 感染可以抑制抗瘤免疫力.
- 肝细胞癌 (HCC) 患者经常对免疫检查点抑制剂 (ICI) 疗法表现出耐药性.
- 杆菌对HCC患者ICI治疗结果的影响需要进一步调查.
研究的目的:
- 评估H. pylori血清状况与接受ICI或sorafenib治疗的HCC患者的治疗结果之间的关联.
- 确定 H. pylori 感染是否影响 HCC 治疗 ICI 和 sorafenib 的疗效和安全性.
主要方法:
- 一项多中心研究包括180名HCC患者,这些患者接受了基于ICI的组合疗法或基于索拉芬尼布的治疗.
- 评估了H. pylori的血清状况和毒性因素.
- 整体存活率 (OS),无进展存活率 (PFS) 和安全性与治疗组中的H. pylori状态相关.
主要成果:
- 在ICI治疗的64名患者中,H. pylori阳性个体的中位寿命明显较短 (10.9个月与18.3个月,p=0.0384) 和PFS (3.9个月与6.8个月,p=0.0499).
- 在接受索拉费尼布治疗的116名患者中,H. pylori阳性与减少的生存寿命没有相关性 (13.4个月与10.6个月,p=0.3353).
- 在两个治疗组中的H. pylori阳性和阴性患者之间,不良事件是可比的.
结论:
- H. pylori 血清阳性与 ICI 治疗的 HCC 患者的治疗结果较差有关.
- 在接受基于索拉费尼布的治疗的HCC患者中没有观察到这种负面关联.
- H. pylori 状态可能是 HCC 中 ICI 响应的预测因素.
更多相关视频
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
319
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
319
Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
344
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
344
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


